Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for the DurAVR^® THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 ± 37mm²). The DurAVR^® THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% freedom from moderate or severe prosthesis-patient mismatch^* (PPM) in a cohort of small annuli patients similar to the one reported in the SMART Trial¹.

Read more at globenewswire.com